Purpose Multidimensional unfolding is a multivariate method to assess preferences using a small sample size, a geometric model locating individuals and alternatives as points in a joint space. The objective was to evaluate relapsing–remitting multiple sclerosis (RRMS) patient preferences toward key disease-modifying therapy (DMT) attributes using multidimensional unfolding. Patients and methods A cross-sectional pilot study in RRMS patients was conducted. Drug attributes included relapse prevention, disease progression prevention, side-effect risk and route and schedule of administration. Assessment of preferences was performed through a five-card game. Patients were asked to value attributes from 1 (most preferred) to 5 (least preferr...
Understanding the preferences of patients with multiple sclerosis (MS) for disease-modifying drugs a...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
José Manuel Garcia-Dominguez,1 Delicias Muñoz,2 Marta Comellas,3 Irmina Gonzalbo,3 Lui...
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes...
Objective. Quantitatively summarize patient preferences for European licensed relapsing-remitting mu...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Objective: To assess heterogeneity in patient and physician preferences for multiple sclerosis treat...
OBJECTIVES: Understanding the preferences of patients with multiple sclerosis (MS) for disease-modif...
Objectives: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis ...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
ObjectivesUnderstanding the preferences of patients with multiple sclerosis (MS) for disease-modifyi...
Background: Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease o...
Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease of the centra...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Understanding the preferences of patients with multiple sclerosis (MS) for disease-modifying drugs a...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
José Manuel Garcia-Dominguez,1 Delicias Muñoz,2 Marta Comellas,3 Irmina Gonzalbo,3 Lui...
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes...
Objective. Quantitatively summarize patient preferences for European licensed relapsing-remitting mu...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Objective: To assess heterogeneity in patient and physician preferences for multiple sclerosis treat...
OBJECTIVES: Understanding the preferences of patients with multiple sclerosis (MS) for disease-modif...
Objectives: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis ...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
ObjectivesUnderstanding the preferences of patients with multiple sclerosis (MS) for disease-modifyi...
Background: Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease o...
Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease of the centra...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Understanding the preferences of patients with multiple sclerosis (MS) for disease-modifying drugs a...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...